{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:43Z","timestamp":1791206383190,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Soluble gp130 is the naturally occurring antagonist of the interleukin\u20106 (IL\u20106)\/soluble IL\u20106 receptor (sIL\u20106R) complex and selectively inhibits IL\u20106 trans\u2010signaling. Several isoforms of soluble gp130 have been identified, including an autoantigenic form termed gp130\u2010RAPS (for gp130 of the rheumatoid arthritis antigenic peptide\u2013bearing soluble form) that is present in the serum and synovial fluid of patients with rheumatoid arthritis. The aim of this study was to evaluate the functional properties of gp130\u2010RAPS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To define a role for gp130\u2010RAPS in arthritis, a recombinant version was generated using a baculovirus expression system, and its activities were tested in vitro and in vivo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Gp130\u2010RAPS was shown to bind with high affinity to the stable IL\u20106\/sIL\u20106R complex, hyper\u2013IL\u20106, and to effectively modulate leukocyte migration in murine acute peritonitis. A single intraarticular injection of gp130\u2010RAPS suppressed chronic antigen\u2010induced arthritis in association with a reduction in local activation of signal transducer and activator of transcription 3. Although gp130\u2010RAPS contains the previously identified autoantigenic sequence Asn\u2010Ile\u2010Ala\u2010Ser\u2010Phe (NIASF), no increase in the prevalence of anti\u2013 gp130\u2010RAPS antibodies was observed in serum or synovial fluid obtained from patients with rheumatoid arthritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of inhibitory antibodies to block IL\u20106 responses has shown considerable clinical promise. However, the results presented herein suggest that selective targeting of IL\u20106 trans\u2010signaling may represent a viable alternative to this strategy. In this respect, our present results suggest that the soluble gp130 isoform gp130\u2010RAPS may be useful in the treatment of chronic inflammatory arthritis.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.21818","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T20:23:50Z","timestamp":1146169430000},"page":"1662-1672","source":"Crossref","is-referenced-by-count":88,"title":["Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis"],"prefix":"10.1002","volume":"54","author":[{"given":"Peter J.","family":"Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari A.","family":"Nowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankichi","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"McLoughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri A.","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rose\u2010John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen S.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Topley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.11.2399"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj20030407"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2003.11.003"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.99-1003rev"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2005.25.241"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119821"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3202"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5676"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80334-9"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/75068"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00151-0"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.8.5290"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin\u20106 signal\u2010transducing component gp130 in human serum possessing a potential to inhibit signals through membrane\u2010anchored gp130","volume":"82","author":"Narazaki M","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.020"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200522433"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.17.10798"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7479"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0297-142"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(85)90260-1"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.3.945"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.10.984"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0501794102"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.9.978"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.14.8222"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.4.461"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10623"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20944"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.6.3463"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.4049\/jimmunol.161.11.6347","article-title":"Soluble IL\u20106 receptor potentiates the antagonistic activity of soluble gp130 on IL\u20106 responses","volume":"161","author":"Muller\u2010Newen G","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2001.01867.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.3109\/08977199909069145"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5676"},{"key":"e_1_2_6_34_2","first-page":"1510","article-title":"Concentrations and origins of soluble interleukin\u20106 receptor\u2010\u03b1 in serum and synovial fluid","volume":"24","author":"Desgeorges A","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI13568"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20302"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.21818","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.21818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T07:22:51Z","timestamp":1697008971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.21818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1002\/art.21818"],"URL":"https:\/\/doi.org\/10.1002\/art.21818","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,27]]}}}